Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma · line 2 · Zanubrutinib monotherapy continuous for r/r WM (ASPEN schedule) — alternative to ibrutinib

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	standard
Linked regimen	`REG-ZANUBRUTINIB-WM-RELAPSED`

ID	`IND-WM-2L-ZANUBRUTINIB`
Type	Indication
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-WM`
Sources	`SRC-ESMO-WM-2024` `SRC-NCCN-BCELL-2025`

Notes

STUB — pending Clinical Co-Lead sign-off. Standard-track 2L preferred BTKi for r/r WM. Better cardiac safety vs ibrutinib is dominant advantage. Zanubrutinib NSZU-not-reimbursed; ibrutinib practical fallback if access blocking.

Used By

Algorithms

ALGO-WM-2L - ALGO-WM-2L

Red flag

RF-WM-CXCR4-WHIM-MUTANT - CXCR4 WHIM-like nonsense or frameshift mutation in the C-terminal regulatory domain (e.g....